{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:20:00Z","timestamp":1792790400318,"version":"4.5.0"},"posted":{"date-parts":[[2026,9,20]]},"group-title":"Pharmacology and Therapeutics","reference-count":36,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T00:00:00Z","timestamp":1789862400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Wellcome Trust","award":["206379\/Z\/17\/Z to H.M"],"award-info":[{"award-number":["206379\/Z\/17\/Z to H.M"]}],"id":[{"id":"https:\/\/ror.org\/029chgv08","id-type":"ROR","asserted-by":"crossref"}]},{"name":"U.S. National Institutes of Health","award":["K08 AI141740"],"award-info":[{"award-number":["K08 AI141740"]}],"id":[{"id":"https:\/\/ror.org\/01cwqze88","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,9,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Rifampicin-resistant tuberculosis poses a significant threat worldwide. Clofazimine is considered important for the construction of effective individualized multidrug regimens to treat rifampicin-resistant tuberculosis. Our goal was to characterize clofazimine pharmacokinetics in novel combination treatment regimens and to identify participant characteristics associated with variations in drug exposure.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Clofazimine pharmacokinetic data were obtained from adults and adolescents enrolled in the PandrTB pharmacokinetic sub-study of the endTB and endTB-Q Phase 3 randomized controlled therapeutic trials for rifampicin-resistant tuberculosis. Plasma concentrations were analyzed using nonlinear mixed-effects modeling to quantify clofazimine exposure and explore the impact of relevant covariates.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>\n                    100 participants from six countries with high burdens of rifampicin-resistant tuberculosis contributed pharmacokinetic data. Their median age was 34 years, 32% were female, 18% were living with diabetes mellitus, and 18% were living with HIV. Clofazimine plasma concentration values were best described by a 2-compartment pharmacokinetic model with first-order absorption. Co-administration with delamanid and HIV co-infection resulted in a 37% increase and 20% decrease in clofazimine\u2019s bioavailability, respectively. Diabetes was associated with a 43% decrease in clofazimine clearance. Clofazimine remained in the body for a median of 2.5 years (95\n                    <jats:sup>th<\/jats:sup>\n                    percentile: 0.5 \u2013 8) following 9 months of treatment.\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Co-administration with delamanid, diabetes mellitus, and HIV were associated with variation in clofazimine exposure. We estimated that clofazimine remained present in the body for longer than two years in over half of participants following 9 months of treatment. Follow-up studies are recommended to confirm these associations before adjusting clofazimine dose or clinical care decisions.<\/jats:p>\n                <\/jats:sec>","DOI":"10.64898\/2026.09.18.26363422","type":"posted-content","created":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T21:50:17Z","timestamp":1789941017000},"source":"Crossref","is-referenced-by-count":0,"title":["Clofazimine pharmacokinetics in novel rifampicin-resistant tuberculosis regimens: an analysis of the endTB and endTB-Q trials"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8355-5954","authenticated-orcid":false,"given":"Bernard","family":"Ngara","sequence":"first","affiliation":[{"name":"Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4621-5480","authenticated-orcid":false,"given":"Bel\u00e9n P","family":"Solans","sequence":"additional","affiliation":[{"name":"Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2581-349X","authenticated-orcid":false,"given":"Eunsol","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0365-5841","authenticated-orcid":false,"given":"Pieter","family":"Van Brantegem","sequence":"additional","affiliation":[{"name":"Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0886-9635","authenticated-orcid":false,"given":"Lorenzo","family":"Guglielmetti","sequence":"additional","affiliation":[{"name":"Department of Infectious, Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1837-8031","authenticated-orcid":false,"given":"Francis","family":"Varaine","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2515-5036","authenticated-orcid":false,"given":"Maelenn","family":"Gouillou","sequence":"additional","affiliation":[{"name":"Epicentre, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3455-658X","authenticated-orcid":false,"given":"Carole D.","family":"Mitnick","sequence":"additional","affiliation":[{"name":"Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Division of Global Health Equity, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"},{"name":"Partners In Health, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8415-133X","authenticated-orcid":false,"given":"Allison N.","family":"LaHood","sequence":"additional","affiliation":[{"name":"Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1462-1150","authenticated-orcid":false,"given":"Michael L.","family":"Rich","sequence":"additional","affiliation":[{"name":"Division of Global Health Equity, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"},{"name":"Partners In Health, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0417-4625","authenticated-orcid":false,"given":"Kwonjune J.","family":"Seung","sequence":"additional","affiliation":[{"name":"Division of Global Health Equity, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubbe","family":"Wiesner","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9980-2623","authenticated-orcid":false,"given":"Loren","family":"Hans","sequence":"additional","affiliation":[{"name":"Department of Dietetics and Nutrition, University of the Western Cape, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7786-3117","authenticated-orcid":false,"given":"Rina","family":"Swart","sequence":"additional","affiliation":[{"name":"Department of Dietetics and Nutrition, University of the Western Cape, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6557-9736","authenticated-orcid":false,"given":"Amanzhan","family":"Abubakirov","sequence":"additional","affiliation":[{"name":"Partners In Health, Almaty, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8346-5449","authenticated-orcid":false,"given":"Kanat","family":"Khazhidinov","sequence":"additional","affiliation":[{"name":"Partners In Health, Almaty, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anel","family":"Belgozhanova","sequence":"additional","affiliation":[{"name":"Partners In Health, Almaty, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Mpinda","sequence":"additional","affiliation":[{"name":"Partners In Health, Maseru, Lesotho"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sesomo","family":"Mohale","sequence":"additional","affiliation":[{"name":"Partners In Health, Maseru, Lesotho"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9214-5685","authenticated-orcid":false,"given":"David","family":"Holtzman","sequence":"additional","affiliation":[{"name":"Partners In Health, Maseru, Lesotho"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dante Vargas","family":"V\u00e1squez","sequence":"additional","affiliation":[{"name":"Hospital Nacional Hip\u00f3lito Unanue, Lima, Per\u00fa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny Garc\u00eda","family":"Velarde","sequence":"additional","affiliation":[{"name":"Socios En Salud Sucursal Per\u00fa, Lima, Per\u00fa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0082-3077","authenticated-orcid":false,"given":"Sergio","family":"Mucching-Toscano","sequence":"additional","affiliation":[{"name":"Socios En Salud Sucursal Per\u00fa, Lima, Per\u00fa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6109-7446","authenticated-orcid":false,"given":"Annum","family":"Aftab","sequence":"additional","affiliation":[{"name":"Interactive Research and Development, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahnoor S.","family":"Arshad","sequence":"additional","affiliation":[{"name":"Interactive Research and Development, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0700-2065","authenticated-orcid":false,"given":"Azka","family":"Ashraf","sequence":"additional","affiliation":[{"name":"Indus Hospital and Health Network, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luong V.","family":"Dinh","sequence":"additional","affiliation":[{"name":"National Lung Hospital, Hanoi, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanh T.T.","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Center for Promotion of Advancement of Society, Hanoi, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ha T.T.","family":"Phan","sequence":"additional","affiliation":[{"name":"Center for Promotion of Advancement of Society, Hanoi, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3508-6719","authenticated-orcid":false,"given":"Sean","family":"Wasserman","sequence":"additional","affiliation":[{"name":"Blizard Institute, Queen Mary University of London, London, United Kingdom"},{"name":"Wellcome Discovery Research Platforms in Infection, Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelisiwe","family":"Ntuli","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res Khayelitsha, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3143-5579","authenticated-orcid":false,"given":"Radojka M.","family":"Savic","sequence":"additional","affiliation":[{"name":"Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA"},{"name":"Center for Tuberculosis, UCSF Institute for Global Health Sciences, University of California, San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0982-6226","authenticated-orcid":false,"given":"Helen","family":"McIlleron","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo E.","family":"Vel\u00e1squez","sequence":"additional","affiliation":[{"name":"Center for Tuberculosis, UCSF Institute for Global Health Sciences, University of California, San Francisco, San Francisco, California, USA"},{"name":"Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"PandrTB Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2026092308204418000_2026.09.18.26363422v1.1","unstructured":"Global Tuberculosis Report 2025 [Internet]. [cited 2026 July 27]. Available from: https:\/\/www.who.int\/teams\/global-programme-on-tuberculosis-and-lung-health\/tb-reports\/global-tuberculosis-report-2025"},{"key":"2026092308204418000_2026.09.18.26363422v1.2","doi-asserted-by":"crossref","unstructured":"Ndjeka N , Schnippel K , Master I , et al. High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen. European Respiratory Journal [Internet]. European Respiratory Society; 2018 [cited 2024 Sept 10]; 52(6). Available from: https:\/\/erj.ersjournals.com\/content\/52\/6\/1801528","DOI":"10.1183\/13993003.01528-2018"},{"key":"2026092308204418000_2026.09.18.26363422v1.3","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr444"},{"key":"2026092308204418000_2026.09.18.26363422v1.4","doi-asserted-by":"crossref","unstructured":"Stadler JAM , Maartens G , Meintjes G , Wasserman S . Clofazimine for the treatment of tuberculosis. Front Pharmacol. 2023; 14:1100488.","DOI":"10.3389\/fphar.2023.1100488"},{"key":"2026092308204418000_2026.09.18.26363422v1.5","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201001-0077OC"},{"issue":"11","key":"2026092308204418000_2026.09.18.26363422v1.6","doi-asserted-by":"crossref","first-page":"486","DOI":"10.5588\/ijtldopen.24.0490","article-title":"Updated treatment guidelines for drug-resistant TB: how safe are clofazimine-based regimens?","volume":"1","year":"2024","journal-title":"IJTLD Open"},{"key":"2026092308204418000_2026.09.18.26363422v1.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2503687"},{"key":"2026092308204418000_2026.09.18.26363422v1.8","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00260-15"},{"issue":"3","key":"2026092308204418000_2026.09.18.26363422v1.9","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1080\/17512433.2018.1421067","article-title":"Challenges of using new and repurposed drugs for the treatment of multidrug-resistant tuberculosis in children","volume":"11","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"2","key":"2026092308204418000_2026.09.18.26363422v1.10","first-page":"19","article-title":"Clofazimine as a Treatment for Multidrug-Resistant Tuberculosis: A Review","volume":"89","year":"2021","journal-title":"Scientia Pharmaceutica. Multidisciplinary Digital Publishing Institute"},{"issue":"1","key":"2026092308204418000_2026.09.18.26363422v1.11","first-page":"9","article-title":"Pharmacokinetics of clofazimine in healthy volunteers","volume":"55","year":"1987","journal-title":"Int J Lepr Other Mycobact Dis"},{"key":"2026092308204418000_2026.09.18.26363422v1.12","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa310"},{"key":"2026092308204418000_2026.09.18.26363422v1.13","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198916020-00002"},{"key":"2026092308204418000_2026.09.18.26363422v1.14","doi-asserted-by":"crossref","unstructured":"Howlader S , Kim M-J , Jony MR , et al. Characterization of Clofazimine Metabolism in Human Liver Microsomal Incubation In Vitro. Antimicrob Agents Chemother. 66(10):e00565\u201322.","DOI":"10.1128\/aac.00565-22"},{"issue":"3","key":"2026092308204418000_2026.09.18.26363422v1.15","first-page":"410","article-title":"Clofazimine pharmacokinetics in HIV-infected adults with diarrhea: Implications of diarrheal disease on absorption of orally administered therapeutics","volume":"13","year":"2024","journal-title":"CPT: Pharmacometrics & Systems Pharmacology"},{"key":"2026092308204418000_2026.09.18.26363422v1.16","unstructured":"Study Details | Pharmacometrics to Advance Novel Regimens for Drug-resistant Tuberculosis-PandrTB Tuberculosis | ClinicalTrials.gov [Internet]. [cited 2024 Sept 11]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03827811?cond=pandrtb&rank=1"},{"key":"2026092308204418000_2026.09.18.26363422v1.17","doi-asserted-by":"crossref","unstructured":"Guglielmetti L , Ardizzoni E , Atger M , et al. Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial. Trials. 2021; 22:651.","DOI":"10.1186\/s13063-021-05491-3"},{"issue":"1","key":"2026092308204418000_2026.09.18.26363422v1.18","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1186\/s13063-023-07701-6","article-title":"Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial","volume":"24","year":"2023","journal-title":"Trials"},{"issue":"1","key":"2026092308204418000_2026.09.18.26363422v1.19","doi-asserted-by":"crossref","first-page":"e0079423","DOI":"10.1128\/aac.00794-23","article-title":"Pharmacokinetics and cardiac safety of clofazimine in children with rifampicin-resistant tuberculosis","volume":"68","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"2026092308204418000_2026.09.18.26363422v1.20","first-page":"e38","article-title":"Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development\u2014Part 2: Introduction to Pharmacokinetic Modeling Methods","volume":"2","year":"2013","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"7","key":"2026092308204418000_2026.09.18.26363422v1.21","first-page":"1031","article-title":"The impact of lag time on the estimation of pharmacokinetic parameters","volume":"10","year":"1993","journal-title":"I. One-compartment open model. Pharm Res"},{"key":"2026092308204418000_2026.09.18.26363422v1.22","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-007-9066-0"},{"key":"2026092308204418000_2026.09.18.26363422v1.23","doi-asserted-by":"publisher","DOI":"10.1023\/A:1012299115260"},{"key":"2026092308204418000_2026.09.18.26363422v1.24","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.48.113006.094708"},{"key":"2026092308204418000_2026.09.18.26363422v1.25","unstructured":"NONMEM | Nonlinear Mixed Effects Modelling | ICON plc [Internet]. [cited 2024 Sept 11]. Available from: https:\/\/www.iconplc.com\/solutions\/technologies\/nonmem"},{"key":"2026092308204418000_2026.09.18.26363422v1.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2003.11.003"},{"key":"2026092308204418000_2026.09.18.26363422v1.27","unstructured":"R: The R Project for Statistical Computing [Internet]. [cited 2024 Oct 1]. Available from: https:\/\/www.r-project.org\/"},{"key":"2026092308204418000_2026.09.18.26363422v1.28","doi-asserted-by":"publisher","DOI":"10.1023\/A:1011970125687"},{"issue":"12","key":"2026092308204418000_2026.09.18.26363422v1.29","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1093\/jac\/dkae309","article-title":"A loading dose of clofazimine to rapidly achieve steady-state-like concentrations in patients with nontuberculous mycobacterial disease","volume":"79","year":"2024","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"2026092308204418000_2026.09.18.26363422v1.30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2011.01270.x"},{"issue":"12","key":"2026092308204418000_2026.09.18.26363422v1.31","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1089\/apc.2012.0299","article-title":"Global Impact of Antiretroviral Therapy-Associated Diarrhea","volume":"26","year":"2012","journal-title":"AIDS Patient Care STDS"},{"key":"2026092308204418000_2026.09.18.26363422v1.32","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.13092"},{"key":"2026092308204418000_2026.09.18.26363422v1.33","doi-asserted-by":"crossref","unstructured":"Moore VJ . A review of side-effects experienced by patients taking clofazimine. Leprosy Review [Internet]. 1983 [cited 2025 Jan 22]; 54(4). Available from: http:\/\/leprev.ilsl.br\/pdfs\/1983\/v54n4\/pdf\/v54n4a08.pdf","DOI":"10.5935\/0305-7518.19830039"},{"key":"2026092308204418000_2026.09.18.26363422v1.34","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.12.0144"},{"issue":"7","key":"2026092308204418000_2026.09.18.26363422v1.35","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.3390\/jcm11071927","article-title":"Investigation of Clofazimine Resistance and Genetic Mutations in Drug-Resistant Mycobacterium tuberculosis Isolates","volume":"11","year":"2022","journal-title":"J Clin Med"},{"key":"2026092308204418000_2026.09.18.26363422v1.36","unstructured":"Silva K , Ngara B , Van Brantegem P , et al. CYP3A5 polymorphisms influence bedaquiline and clofazimine pharmacokinetics in clinical trial participants with fluoroquinolone-susceptible and fluoroquinolone-resistant MDR\/RR-TB across six countries. World Conference on Lung Health 2025 of the International Union Against Tuberculosis and Lung Disease. November 18-21, 2025, Copenhagen, Denmark.;"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.09.18.26363422","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:21:01Z","timestamp":1790176861000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.64898\/2026.09.18.26363422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,20]]},"references-count":36,"URL":"https:\/\/doi.org\/10.64898\/2026.09.18.26363422","relation":{},"subject":[],"published":{"date-parts":[[2026,9,20]]},"subtype":"preprint"}}